|
US5128318A
(en)
|
1987-05-20 |
1992-07-07 |
The Rogosin Institute |
Reconstituted HDL particles and uses thereof
|
|
GB8712540D0
(en)
|
1987-05-28 |
1987-07-01 |
Ucb Sa |
Expression of human proapolipoprotein a-i
|
|
US5220043A
(en)
|
1991-03-21 |
1993-06-15 |
Ohio University |
Synthesis of D-erythro-sphingomyelins
|
|
SE9103701D0
(sv)
|
1991-12-13 |
1991-12-13 |
Kabi Pharmacia Ab |
Apolipoprotein
|
|
JP3754072B2
(ja)
|
1994-03-22 |
2006-03-08 |
リサーチ・コーポレーション・テクノロジーズ・インコーポレーテッド |
摂食抑制ペプチド
|
|
US6037323A
(en)
|
1997-09-29 |
2000-03-14 |
Jean-Louis Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
US6046166A
(en)
*
|
1997-09-29 |
2000-04-04 |
Jean-Louis Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
US6004925A
(en)
|
1997-09-29 |
1999-12-21 |
J. L. Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
AU2001257173B2
(en)
|
2000-04-21 |
2005-09-22 |
Amgen Inc. |
Apo-ai/aii peptide derivatives
|
|
US6664230B1
(en)
|
2000-08-24 |
2003-12-16 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
|
US7199102B2
(en)
|
2000-08-24 |
2007-04-03 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
|
US7148197B2
(en)
|
2000-08-24 |
2006-12-12 |
The Regents Of The University Of California |
Orally administered small peptides synergize statin activity
|
|
US7144862B2
(en)
|
2000-08-24 |
2006-12-05 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
|
EP2343317A1
(en)
|
2000-11-10 |
2011-07-13 |
F. Hoffmann-La Roche Ltd. |
Apolipoprotein analogues
|
|
US7217785B2
(en)
|
2001-05-09 |
2007-05-15 |
The Regents Of The University Of California |
Cysteine-containing peptides having antioxidant properties
|
|
CA2457840C
(en)
|
2001-08-20 |
2011-10-11 |
Zlb Bioplasma Ag |
Hdl for the treatment of stroke and other ischemic conditions
|
|
US7223726B2
(en)
|
2002-01-14 |
2007-05-29 |
The Regents Of The University Of California |
Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
|
|
AU2003239489A1
(en)
|
2002-05-17 |
2003-12-02 |
Esperion Therapeutics, Inc. |
Method of treating dyslipidemic disorders
|
|
EP1545576A2
(en)
*
|
2002-07-30 |
2005-06-29 |
Esperion Therapeutics Inc. |
Methods of using non-human animal apoliprotein a-i protein
|
|
EP2314285B2
(en)
|
2003-02-14 |
2019-09-18 |
Children's Hospital & Research Center at Oakland |
Lipophilic drug delivery vehicle and methods of use thereof
|
|
CN101076541A
(zh)
|
2004-07-16 |
2007-11-21 |
塔夫茨大学信托人 |
载脂蛋白a1模拟物及其用途
|
|
US8206750B2
(en)
|
2005-03-24 |
2012-06-26 |
Cerenis Therapeutics Holding S.A. |
Charged lipoprotein complexes and their uses
|
|
AU2006282722A1
(en)
|
2005-08-26 |
2007-03-01 |
Cerenis Therapeutics Holdings S.A. |
Compositions and methods for producing apolipoprotein gene products in lactic acid bacteria
|
|
US8541236B2
(en)
|
2006-12-08 |
2013-09-24 |
University Of Washington |
Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
|
|
WO2008104890A2
(en)
|
2007-02-28 |
2008-09-04 |
Cerenis Therapeutics Holding Sa |
Compositions and methods for producing apolipoprotein
|
|
US9173890B2
(en)
|
2007-09-20 |
2015-11-03 |
Abbott Cardiovascular Systems Inc. |
Sustained release of Apo A-I mimetic peptides and methods of treatment
|
|
EA201070517A1
(ru)
|
2007-10-23 |
2010-12-30 |
Дзе Кливленд Клиник Фаундейшн |
Устойчивый к окислителям аполипопротеин а-1 и пептиды-миметики
|
|
LT2939683T
(lt)
|
2009-02-16 |
2017-03-27 |
Cerenis Therapeutics Holding Sa |
Apolipoproteino a-i mimetikai
|
|
US20130137628A1
(en)
|
2010-05-11 |
2013-05-30 |
Esperion Therapeutics, Inc. |
Dimeric Oxidation-Resistant Apolipoprotein A1 Variants
|
|
EP2673296B1
(en)
*
|
2011-02-07 |
2018-10-24 |
Cerenis Therapeutics Holding SA |
Lipoprotein complexes and manufacturing and uses thereof
|
|
JP6438417B2
(ja)
|
2013-03-15 |
2018-12-12 |
セレニス セラピューティクス ホールディング エスアー |
スフィンゴミエリンおよびジヒドロスフィンゴミエリンの合成のための方法
|
|
US9708354B2
(en)
|
2013-03-15 |
2017-07-18 |
Cerenis Therapeutics Holding Sa |
Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
|
|
EP2853259A1
(en)
*
|
2013-09-30 |
2015-04-01 |
Université Pierre et Marie Curie (Paris 6) |
Reconstituted high density lipoproteins composition and uses thereof
|
|
WO2015173633A2
(en)
|
2014-05-02 |
2015-11-19 |
Cerenis Therapeutics Holding Sa |
Hdl therapy markers
|
|
WO2018029505A1
(en)
*
|
2016-08-11 |
2018-02-15 |
Cerenis Therapeutics Holding Sa |
Cer-001 therapy for treating familial primary hypoalphalipoproteinemia
|
|
FR3100715B1
(fr)
*
|
2019-09-12 |
2023-09-29 |
Francais Du Sang Ets |
Utilisation de HDL dans la prophylaxie de la maladie du greffon contre l’hôte
|